After adjusting for sex and age, RUNX3-/SMAD4+ status remained a significant independent predictive factor for favorable overall [p = 0.025, HR 1.842 (95% CI 1.079–3.143)] and progression-free survival [p = 0.020, HR 1.850 (95% CI 1.100–3.113)] on multivariate analysis, in addition to tumor size (Table 5). The gene discussed is RUNX3; the disease is neoplasm.